Clinical Trial Update: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating maintenance retreatment with olaparib in epithelial ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Epithelial Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-04-19